Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | USP7 | Q93009 | 1/20 | 0.40 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24976104 | 0.86 | KDM2B (0.41) | SCN9AMEN1KMT2AKDM2BNPC1 | |
| SCHEMBL31428645 | 0.83 | HPGD (0.57) | HPGDTSHRKMT2AALDH1A1MAPT | |
| SCHEMBL30163530 | 0.83 | SCN9A (0.54) | HPGDTSHRSCN9AKDM2B | |
| SCHEMBL31428690 | 0.82 | SCN9A (0.44) | HPGDTSHRSCN9AMEN1KMT2A | |
| SCHEMBL31428689 | 0.82 | SCN9A (0.44) | HPGDTSHRSCN9AMEN1KMT2A | |
| SCHEMBL23742769 | 0.81 | HRH3 (0.49) | HPGDTSHR | |
| SCHEMBL31428718 | 0.79 | HPGD (0.55) | HPGDTSHRMEN1KMT2AALDH1A1 | |
| SCHEMBL31428951 | 0.77 | HPGD (0.53) | HPGDALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL30163534 | 0.77 | L3MBTL3 (0.47) | HPGDTSHRMEN1KMT2AKDM2B | |
| SCHEMBL31428443 | 0.76 | PKM (0.53) | HPGDTSHRKMT2AKDM2BNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) | 2025-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250091994-A1 | RAS/RAF BINDING INHIBITOR COMPOUND | BRAF, RAF1, NRAS | HPGD 4233/4885TSHR 1389/4885SCN9A 3259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.